Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:861
Published online before print January 18, 2007, doi: 10.1161/01.STR.0000257311.88235.fc
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/861    most recent
01.STR.0000257311.88235.fcv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toyoda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyoda, K.

(Stroke. 2007;38:861.)
© 2007 American Heart Association, Inc.


Letters to the Editor

Response to Letter by Tsivgoulis et al

Kazunori Toyoda, MD, PhD

Cerebrovascular Division, National Cardiovascular Center, Suita, Osaka, Japan

Response:

We appreciate the interest of Tsivgoulis et al in our article on blood pressure (BP) course during the initial week after different subtypes of ischemic stroke.1 Among methodological issues of our study which their letter raises, the most essential one appears to be relatively frequent use of antihypertensives or coronary vasodilators during acute stroke in the cardioembolic patients. On admission, ultrasound and magnetic resonance angiography were performed for almost all of our stroke patients to detect cerebrovascular occlusion/stenosis which might cause cerebral hypoperfusion. For patients without such vascular lesions, who had extremely high BP or severe cardiovascular comorbidities, we did not hesitate to lower acute BP to some extent. Our recent study2 showed that advanced renal damage, as well as poorly controlled diabetes mellitus, was related to high acute BP during the first 36 hours of hospitalization which met the criteria of the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study.3 Early treatment with antihypertensives, including an angiotensin type 1 receptor blocker, might be protective against progression of such organ damages. Several ongoing trials may change strategies for BP management during acute stroke in the near future.

Acknowledgments

Disclosures

None.

References

1. Toyoda K, Okada Y, Fujimoto S, Hagiwara N, Nakachi K, Kitazono T, Ibayashi S, Iida M. Blood pressure changes during the initial week after different subtypes of ischemic stroke. Stroke. 2006; 37: 2637–2639.[Abstract/Free Full Text]

2. Toyoda K, Okada Y, Jinnouchi J, Gotoh S, Yokoyama Y, Fujimoto S, Ibayashi S. High blood pressure in acute ischemic stroke and underlying disorders. Cerebrovasc Dis. 2006; 22: 355–361.[CrossRef][Medline] [Order article via Infotrieve]

3. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003; 34: 1699–1703.[Abstract/Free Full Text]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/861    most recent
01.STR.0000257311.88235.fcv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toyoda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyoda, K.